COMPANY PROFILE

Selecxin

Explore full profile

Innovative immunotherapeutics development through unique technology and active research collaboration

Seoul, South KoreaFounded 2018Biotech & Life Sciences

Valuation $100–250M Last recorded · 2022

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Selecxin

Selecxine is a biotechnology company focused on the development of effective immunotherapeutics to improve the quality of life. The company leverages its unique technology and active research collaborations to create differentiated antibody solutions. Selecxine operates in the biopharmaceutical market, primarily serving healthcare providers and research institutions. The business model revolves around the research and development of novel antibodies, which are then licensed or sold to pharmaceutical companies. Revenue is generated through licensing agreements, research grants, and partnerships with larger pharmaceutical firms.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2018
Headquarters: Seoul, South Korea
Employees: 9
Open positions: None listed
Dealroom signal: 47.2/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Immunotherapy, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES B✓Equity / VC	Mar 2022	$28M	$111M	Medytox Investments · Medici Investment · Hi Investment Partners · UTC Investment	↗
OtherOther financing	Nov 2020	$0	—	STIC Ventures	↗

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Selecxin website traffic

Latest recorded traffic for Selecxin is 660 monthly website visits, down 81.7% over the last three months. Selecxin's team grew 0% over the past year.

Latest monthly visits660 3-month web change-81.7% 1-year team growth0%

Monthly website visitsDec 2020–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ATAllotera TherapeuticsDeveloping off-the-shelf cellular therapies for cancer	St. Louis, United States	Operational	47	$351M	$860M
ETEmergence TherapeuticsEuropean biopharmaceutical company developing novel ADC immuno-therapeutics to treat high-unmet need cancers	Duisburg, Germany	Acquired
ATAtsena TherapeuticsBringing the life-changing power of genetic medicine to reverse or prevent blindness	Durham, United States	Operational
ADAdaptateDeveloping therapeutic antibodies to modulate gamma delta T cell activity for innovative immunotherapy solutions	London, United Kingdom	Acquired
SPSpectropathAn imaging technology company that allows physicians to immediately recognize targeted tissues such as cancer in real time during surgery, therapeutic, or diagnostic procedures	Atlanta, United States	Closed
SBSensei BiotherapeuticsAn innovator in the field of next-generation cancer immunotherapies	Gaithersburg, United States	Operational
OLOlgramInnovations from the sea to tackle antibiotic resistance \| Olgram	Paris, France	Operational
LULucencePrecision oncology company dedicated to creating state-of-the-art, highly sensitive liquid biopsy tests for early disease detection and personalized treatment selection	Palo Alto, United States	Operational